Private Advisor Group LLC Has $17.66 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Private Advisor Group LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 665,476 shares of the biopharmaceutical company's stock after selling 184,109 shares during the period. Private Advisor Group LLC's holdings in Pfizer were worth $17,655,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Swedbank AB increased its position in shares of Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock worth $166,284,000 after purchasing an additional 37,636 shares during the last quarter. Copeland Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter worth about $144,000. Sequoia Financial Advisors LLC increased its position in shares of Pfizer by 55.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 422,143 shares of the biopharmaceutical company's stock worth $12,217,000 after purchasing an additional 151,293 shares during the last quarter. Eastern Bank increased its position in shares of Pfizer by 481.4% in the 3rd quarter. Eastern Bank now owns 107,466 shares of the biopharmaceutical company's stock worth $3,110,000 after purchasing an additional 88,982 shares during the last quarter. Finally, Symphony Financial Ltd. Co. increased its position in shares of Pfizer by 19.1% in the 3rd quarter. Symphony Financial Ltd. Co. now owns 41,106 shares of the biopharmaceutical company's stock worth $1,181,000 after purchasing an additional 6,586 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.52 during trading on Friday, reaching $26.42. The company had a trading volume of 39,866,963 shares, compared to its average volume of 38,022,176. The firm's fifty day moving average is $26.28 and its 200 day moving average is $27.44. The firm has a market capitalization of $149.73 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business posted $0.10 EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.51%. Pfizer's dividend payout ratio is currently 121.99%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a "buy" rating and set a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. Finally, Bank of America reissued a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.